contractpharmaAugust 30, 2017
Tag: FDA , PBOA , GDUFA Rates , manufacturing organization facilities , fiscal year 2018
The FDA has released the Generic Drug User Fee Amendments (GDUFA) rates for contract manufacturing organization facilities of fiscal year 2018.
GDUFA is Generic Drug User Fee Amendments of FDA.
The CMO finished dosage form (FDF) facility fee for FY18 is $70,362 for a U.S. site, and $85,362 for a non-U.S. site. According to PBOA president Gil Roth, this fee is a significant drop from FY17's FDF fee of $258,646. The non-CMO FDF fee is $211,087 for a U.S. site and $226,087 for a non-U.S. site. According to Mr. Roth, if the PBOA was not at the negotiating table and the GDUFA I fee formula was applied to GDUFA II's fee base of $493,600,000, the FDF fee would have been in excess of $440,000 per facility.
Under GDUFA II, CMO sites are defined as facilities that are not referenced in an approved ANDA held by the owner of that facility or its affiliates. If the parent company owns an approved ANDA and it references the CMO site, that site is not eligible for the reduced fee.
Below includes the GDUFA II fee breakdown beginning October 1:
Recurring Fees
FDF facility fee, US, non-CMO: $211,087
FDF facility fee, ex-US, non-CMO: $226,087
FDF facility fee, US, CMO: $70,362
FDF facility fee, ex-US, CMO: $85,362
API facility fee, US: $45,367
API facility fee, ex-US: $60,367
ANDA Holder fee, 1-5 approved ANDAs: $159,079
ANDA Holder fee, 6-19 approved ANDAs: $636,317
ANDA Holder fee, 1-5 approved ANDAs: $1,590,792
One-Time Fees
ANDA filing fee: $171,823
DMF filing fee: $47,829
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: